A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (BC)

被引：0
|
作者：
Beeram, M.
Krop, I.
Modi, S.
Tolcher, A.
Rabbee, N.
Girish, S.
Tibbitts, J.
Holden, S.
Lutzker, S.
Burris, H.
机构：
[1] Inst Drug Dev, San Antonio, TX USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] Sarah Cannon Canc Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042
引用
收藏
页数：1
相关论文
共 50 条
  • [21] TARGETING HER2 WITH TRASTUZUMAB-DM1 (T-DM1) IN HER2-OVEREXPRESSING BLADDER CANCER
    Hayashi, Tetsutaro
    Jaeger, Wolfgang
    Moskalev, Igor
    Awrey, Shannon
    Li, Na
    Fazli, Ladan
    Yasui, Wataru
    Matsubara, Akio
    Black, Peter
    JOURNAL OF UROLOGY, 2014, 191 (04): : E301 - E301
  • [22] Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+metastatic breast cancer
    Niculescu-Duvaz, Ion
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010, 12 (03) : 350 - 360
  • [23] CLINICAL PHARMACOLOGY OF T-DM1: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) IN DEVELOPMENT FOR THE TREATMENT OF HER2-POSITIVE (HER2+) CANCER
    Girish, S.
    Gupta, M.
    Wang, B.
    Lu, D.
    Krop, I.
    Vogel, C.
    Burris, H.
    Yi, J.
    Saad, O.
    Tong, B.
    Klencke, B.
    Agresta, S.
    Chu, W.
    Joshi, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S12 - S12
  • [24] A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+breast cancer
    Krop, I. E.
    Mita, M.
    Burris, H. A.
    Birkner, M.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Modi, S.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
  • [25] Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer
    Hayashi, Tetsutaro
    Seiler, Roland
    Oo, Htoo Zarni
    Jaeger, Wolfgang
    Moskalev, Igor
    Awrey, Shannon
    Dejima, Takashi
    Todenhoefer, Tilman
    Li, Na
    Fazli, Ladan
    Matsubara, Akio
    Black, Peter C.
    JOURNAL OF UROLOGY, 2015, 194 (04): : 1120 - 1131
  • [26] Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
    Lu, Dan
    Girish, Sandhya
    Gao, Yuying
    Wang, Bei
    Yi, Joo-Hee
    Guardino, Ellie
    Samant, Meghna
    Cobleigh, Melody
    Rimawi, Mothaffar
    Conte, Pierfranco
    Jin, Jin Yan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 399 - 410
  • [27] Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer
    Girish, Sandhya
    Gupta, Manish
    Wang, Bei
    Lu, Dan
    Krop, Ian E.
    Vogel, Charles L.
    Burris, Howard A., III
    LoRusso, Patricia M.
    Yi, Joo-Hee
    Saad, Ola
    Tong, Barbara
    Chu, Yu-Waye
    Holden, Scott
    Joshi, Amita
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1229 - 1240
  • [28] HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
    Rinnerthaler, Gabriel
    Gampenrieder, Simon Peter
    Greil, Richard
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (05)
  • [29] Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer
    Jain, S.
    Nye, L.
    Santa-Maria, C.
    Bontemps, L.
    Williams, A.
    Garrett, H.
    Dammrich, E.
    Giles, F.
    Gradishar, W.
    CANCER RESEARCH, 2016, 76
  • [30] Synthesized Anti-HER 2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity
    Shafiee, Soodabeh
    Mirzaei, Roya
    Salehi, Malihe
    Jalili, Neda
    Taheri, Amir
    Farahmand, Leila
    IRANIAN JOURNAL OF IMMUNOLOGY, 2023, 20 (03) : 303 - 315
12345